Jirka Taylor

Photo of Jirka Taylor
Analyst
Washington Office

Education

M.Phil. in international relations, University of Cambridge; M.A. in American studies, Charles University, Prague; B.A. in international area studies, Charles University, Prague

Media Resources

This researcher is available for interviews.

To arrange an interview, contact RAND Europe Media Relations at +44 (1223) 353 329, x2560, or email europeanmedia@rand.org.

More Experts

Overview

Jirka Taylor is a RAND Europe analyst working in the area of home affairs and social policy. His research interests include health, social, criminal justice and development policy, particularly from an evaluation perspective.

Taylor has co-authored studies on the global costs of antimicrobial resistance and on the costs of corruption in the EU, which included an assessment of existing and potential EU measures in the fight against corruption. Currently, he is working on a mid-term evaluation of the 2013-2020 EU Drugs Strategy and an assessment of the implementation of the associated EU Action Plan on Drugs.

While at RAND, Taylor has been involved in a range of other EU-level evaluations, including an estimation of costs associated with the reintroduction of border controls within the Schengen Area and an evaluation of the EU Action Plan on antimicrobial resistance. Other projects in his portfolio include a series of programme evaluations and reviews for the UK Department for International Development.

Taylor received his M.A. from the Faculty of Social Sciences, Charles University, Prague, and his M.Phil. from the University of Cambridge. Before joining RAND, he worked as an intern for the Broadcasting Board of Governors and for the office of the president at Radio Free Europe/Radio Liberty.

Commentary

  • A memorial stone for the Schengen Agreement is seen in the small village of Schengen, Luxembourg January 27, 2016

    Why Re-Establishing Border Controls in Europe Could Come at a High Cost

    Reversing the Schengen agreement would come at a high economic cost, while undoing many of the positive social and political developments of the past decade.

    Oct 13, 2016 E!Sharp

  • Antibiotic syringe near a quail cage in partridge farm

    Why the United Nations General Assembly Session on Antimicrobial Resistance Matters

    Many common infections are becoming resistant to the antimicrobial medicines used to treat them, resulting in longer illnesses and more deaths. The fact that world leaders are using the UN as a forum for discussions about AMR is a promising move toward developing a coordinated global plan.

    Sep 19, 2016 The RAND Blog

  • Two scientists in protective gear working in a microbiology laboratory

    European and American Efforts to Tackle AMR: Great Minds Think Alike (Almost Always)

    The U.S. and the EU are committed to tackling antimicrobial resistance. Their efforts share objectives around key areas for improvement, such as the stewardship of existing antimicrobials, surveillance of their use, and development of new antimicrobials.

    Aug 19, 2016 The Health Care Blog

  • Ukraine's Olympic rowers training in Rio de Janeiro, Brazil, July 26, 2016

    The Rio Olympics Are the Site of a Battle Against 'Super Bacteria'

    Brazilian scientists detected drug-resistant bacteria growing off some of Rio de Janeiro's beaches, close to where it will host sailing and wind-surfing events, and in the lagoon where the rowing and canoeing events will take place.

    Jul 29, 2016 Medical Xpress

  • Hereford cattle eating at a trough

    The Global Economic Costs of Antimicrobial Resistance

    In addition to being a public health problem, antimicrobial resistance is also a major economic concern. It crosses sectoral boundaries, because resistant bugs can pass between animals and humans, and through food, agriculture, and the environment.

    May 20, 2016 Cultures Magazine

  • A world map shaped with pharmaceutical drugs

    The O'Neill Review: A Critical Step in Taking Global Action Against AMR

    The O'Neill Review aims to increase global knowledge of antimicrobial resistance (AMR) and generate international consensus about the nature of the problem and the necessary steps to tackle it. A RAND Europe analysis of the potential economic costs of AMR contributed to the Review.

    May 19, 2016 The RAND Blog

  • Girl holding balloons

    Does Increased Social Spending Lead to Better Population Health?

    Higher levels of social spending are strongly associated with better health outcomes in many countries, with this link strengthening over time. The association also holds when looking at regional differences within the United States, where spending varies state-by-state.

    May 11, 2016 The RAND Blog

  • An envelope full of 500 euro notes

    The True Economic Cost of Corruption in Europe: Up to €990 Billion Annually

    Corruption costs Europe up to €990 billion in GDP annually, according to a new study. That's more than eight times previous estimates.

    Mar 22, 2016 E!Sharp

  • A green bacteria colony

    The Cost of Resistance and the Attack of the Microbes

    If left unaddressed, the threat posed by antimicrobial resistance and the rise of 'superbugs' could devastate the world economy and pose a deadly threat to humanity.

    Aug 7, 2015 LifeZette

  • A scientist wearing a respirator while looking at a Petri dish

    G7 Leaders to Discuss Threat of Antimicrobial Resistance

    The threat of drug resistance can be tackled with the right set of actions, including the development of new antimicrobial drugs and alternative therapies to disrupt the rise in resistance. German Chancellor Merkel has emphasized the importance of a joint global action plan for addressing this growing problem.

    Jun 8, 2015 The RAND Blog

  • High-resolution 3D rendering of bacteria under a scanning microscope

    Ringing the Alarm Bell for Antimicrobial Resistance

    The increase in the number of bacterial and viral infections that are resistant to antimicrobial drugs poses a growing global health threat.

    Feb 20, 2015 The RAND Blog

  • American pharmacist with senior woman in pharmacy

    The Most Dangerous Mistake You Can Make During Flu Season

    Despite public awareness campaigns in the United States and Europe, many people persist in the mistaken belief that antibacterial drugs — like amoxicillin and azithromycin — are the best treatment for flu. And many doctors simply surrender when patients demand them, ignoring the scientific and medical truth: when treating the flu, antibacterial drugs just don't work.

    Oct 28, 2013 Reuters, The Great Debate blog

  • viruses and bacteria under a microscope

    Who Killed Mrs X? The Global Threat of Antimicrobial Resistance

    Antimicrobial drugs are no longer working as they once did. The bugs that they are supposed to attack are becoming increasingly resistant. Microbes follow the same rules of evolution as we do. Through reproduction and natural selection the fittest survive.

    Sep 18, 2013 The RAND Blog

Publications